| __timestamp | Agios Pharmaceuticals, Inc. | Bausch Health Companies Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 2026300000 |
| Thursday, January 1, 2015 | 35992000 | 2682700000 |
| Friday, January 1, 2016 | 50714000 | 2810000000 |
| Sunday, January 1, 2017 | 71124000 | 2582000000 |
| Monday, January 1, 2018 | 114145000 | 2473000000 |
| Tuesday, January 1, 2019 | 132034000 | 2554000000 |
| Wednesday, January 1, 2020 | 149070000 | 2367000000 |
| Friday, January 1, 2021 | 121445000 | 2624000000 |
| Saturday, January 1, 2022 | 121673000 | 2625000000 |
| Sunday, January 1, 2023 | 119903000 | 2917000000 |
| Monday, January 1, 2024 | 156784000 |
Infusing magic into the data realm
Over the past decade, the Selling, General, and Administrative (SG&A) expenses of Bausch Health Companies Inc. and Agios Pharmaceuticals, Inc. have painted a vivid picture of contrasting business strategies. Bausch Health, a giant in the pharmaceutical industry, consistently reported SG&A expenses that were approximately 25 times higher than those of Agios Pharmaceuticals. This disparity highlights Bausch's expansive operational scale and market reach.
From 2014 to 2023, Agios Pharmaceuticals saw a steady increase in SG&A expenses, peaking in 2020 with a 680% rise from 2014. Meanwhile, Bausch Health's expenses fluctuated, with a notable peak in 2023, marking a 44% increase from its 2014 figures. These trends reflect the companies' differing growth trajectories and market strategies, offering valuable insights for investors and industry analysts alike.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Bausch Health Companies Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Grifols, S.A. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.